TY - JOUR
T1 - Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation
AU - Caglayan, Safak
AU - Takagi-Niidome, Shizuka
AU - Liao, Fan
AU - Carlo, Anne Sophie
AU - Schmidt, Vanessa
AU - Burgert, Tilman
AU - Kitago, Yu
AU - Fuc̈htbauer, Ernst Martin
AU - Fuc̈htbauer, Annette
AU - Holtzman, David M.
AU - Takagi, Junichi
AU - Willnow, Thomas E.
PY - 2014/2/12
Y1 - 2014/2/12
N2 - SORLA/SORL1 is a unique neuronal sorting receptor for the amyloid precursor protein that has been causally implicated in both sporadic and autosomal dominant familial forms of Alzheimer's disease (AD). Brain concentrations of SORLA are inversely correlated with amyloid-β (Aβ) in mouse models and AD patients, suggesting that increasing expression of this receptor could be a therapeutic option for decreasing the amount of amyloidogenic products in affected individuals. We characterize a new mouse model in which SORLA is overexpressed, and show a decrease in Aβ concentrations in mouse brain. We trace the underlying molecular mechanism to the ability of this receptor to direct lysosomal targeting of nascent Ab peptides. Ab binds to the amino-terminal VPS10P domain of SORLA, and this binding is impaired by a familial AD mutation in SORL1. Thus, loss of SORLA's Aβ sorting function is a potential cause of AD in patients, and SORLA may be a new therapeutic target for AD drug development.
AB - SORLA/SORL1 is a unique neuronal sorting receptor for the amyloid precursor protein that has been causally implicated in both sporadic and autosomal dominant familial forms of Alzheimer's disease (AD). Brain concentrations of SORLA are inversely correlated with amyloid-β (Aβ) in mouse models and AD patients, suggesting that increasing expression of this receptor could be a therapeutic option for decreasing the amount of amyloidogenic products in affected individuals. We characterize a new mouse model in which SORLA is overexpressed, and show a decrease in Aβ concentrations in mouse brain. We trace the underlying molecular mechanism to the ability of this receptor to direct lysosomal targeting of nascent Ab peptides. Ab binds to the amino-terminal VPS10P domain of SORLA, and this binding is impaired by a familial AD mutation in SORL1. Thus, loss of SORLA's Aβ sorting function is a potential cause of AD in patients, and SORLA may be a new therapeutic target for AD drug development.
UR - http://www.scopus.com/inward/record.url?scp=84896360551&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3007747
DO - 10.1126/scitranslmed.3007747
M3 - Article
C2 - 24523320
AN - SCOPUS:84896360551
SN - 1946-6234
VL - 6
JO - Science translational medicine
JF - Science translational medicine
IS - 223
M1 - 223ra20
ER -